TrialThe New England journal of medicine2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
David Adams et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,489 papers cite itlatest 60 shown
this paperpooled ittrialcites it